Royalty Pharma Boosts Executive Equity to Drive M&A and Patent-Cliff Wins
Royalty Pharma’s latest equity filings reveal a strategic push to align executive incentives, strengthen governance, and boost M&A agility, positioning the company to seize patent‑cliff opportunities and expand its $15 billion royalty portfolio.
5 minutes to read


